79 related articles for article (PubMed ID: 21247547)
1. Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia.
Cho EJ; Min YJ; Oh MS; Kwon JE; Kim JE; Kim CJ
Am J Cardiol; 2011 Mar; 107(5):793-6. PubMed ID: 21247547
[TBL] [Abstract][Full Text] [Related]
2. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
Pitt B; Waters D; Brown WV; van Boven AJ; Schwartz L; Title LM; Eisenberg D; Shurzinske L; McCormick LS
N Engl J Med; 1999 Jul; 341(2):70-6. PubMed ID: 10395630
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
4. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
5. Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
Burnside NJ; Alberta L; Robinson-Bostom L; Bostom A
J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S281-4. PubMed ID: 16227109
[TBL] [Abstract][Full Text] [Related]
6. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
Stone PH; Lloyd-Jones DM; Kinlay S; Frei B; Carlson W; Rubenstein J; Andrews TC; Johnstone M; Sopko G; Cole H; Orav J; Selwyn AP; Creager MA;
Circulation; 2005 Apr; 111(14):1747-55. PubMed ID: 15809368
[TBL] [Abstract][Full Text] [Related]
7. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
Smelt AH
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
[TBL] [Abstract][Full Text] [Related]
8. Familial dysbetalipoproteinemia: a potentially fatal disorder.
Bari AU; Hashim R; Rahman SB; Hussain M
J Coll Physicians Surg Pak; 2008 Aug; 18(8):506-8. PubMed ID: 18798589
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia.
Kinlay S; Timms T; Clark M; Karam C; Bilodeau T; Ridker PM; Rifai N; Carlson W; Lloyd-Jones DM; Johnstone M; Rubenstein J; Alexander S; Orav J; Stone PH;
Am J Cardiol; 2002 May; 89(10):1205-7. PubMed ID: 12008177
[No Abstract] [Full Text] [Related]
10. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Canzler H; Bojanovski D
Artery; 1980; 8(2):171-8. PubMed ID: 7458684
[TBL] [Abstract][Full Text] [Related]
11. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Milionis HJ; Bairaktari ET; Liberopoulos EN; Elisaf MS
Am J Cardiol; 2001 Jul; 88(2):203. PubMed ID: 11463061
[No Abstract] [Full Text] [Related]
13. Effect of fenofibrate treatment on type III hyperlipoproteinemia.
Fruchart JC; Davignon J; Bard JM; Grothe AM; Richard A; Fievet C
Am J Med; 1987 Nov; 83(5B):71-4. PubMed ID: 3688011
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
Feussner G; Kurth B; Lohrmann J
Eur J Med Res; 1997 Apr; 2(4):165-8. PubMed ID: 9110923
[TBL] [Abstract][Full Text] [Related]
15. [Congenital anomalies of the coronary arteries with associated ischemic ST depression on exercise: a report of three cases].
Naito H; Yorozu T; Maeda T; Shiomi K; Seki K; Tanabe Y; Tada T; Nakashima H
J Cardiol; 1990; 20(2):499-508. PubMed ID: 2104424
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
Stuyt PM; Mol MJ; Stalenhoef AF; Demacker PN; Van 't Laar A
Am J Med; 1990 Jan; 88(1N):42N-45N. PubMed ID: 2368763
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis.
Zhang B; Katafuchi R; Arishima H; Matsunaga A; Rye KA; Saku K
Clin Chim Acta; 2006 Nov; 373(1-2):55-61. PubMed ID: 16806136
[TBL] [Abstract][Full Text] [Related]
19. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
20. Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment.
Solem J; Levin M; Karlsson T; Grip L; Albertsson P; Wiklund O
J Intern Med; 2006 Mar; 259(3):267-75. PubMed ID: 16476104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
